Page 74 - Looking Statement News Today

Las Vegas, NV, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Suntex Enterprises Inc. (OTC Pink: SNTX) is pleased to update shareholders and the public about the...

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2021 financial results and host a conference call after...

Press release content from Accesswire. The AP news staff was not involved in its creation.

DGAP-News: Kadimastem Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement 25.10.2021 / 14:09 The issuer is solely...

/PRNewswire/ - New Found Gold Corp. ("New Found" or the "Company") (TSXV: NFG) (NYSE American: NFGC) is pleased to announce an expansion of the exploration...

If Granted Marketing Authorization by the European Commission, Molnupiravir Could Be the First Oral Antiviral Medicine for the Treatment of COVID-19 in the European Union Merck known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the European Medicines Agency has initiated a rolling review for molnupiravir, an investigational oral antiviral medicine, for the treatment ...

KEYTRUDA Is Now Approved in Combination With Chemotherapy as First-Line Treatment for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 and Who Have Not Received Prior Chemotherapy for Metastatic Disease KEYTRUDA Is the First Anti-PD-1 Therapy in Combination With Chemotherapy to Demonstrate Statistically Significant Overall Survival in These Patients; Based on Results From ...

Series Would be Routinely Recommended Both for Adults 65 Years and Older and for Adults Ages 19 to 64 at Increased Risk for Disease, Such as Those with Certain Underlying Medical Conditions Merck known as MSD outside the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices unanimously voted in favor of updates to pneumococcal ...

/PRNewswire/ - New Found Gold Corp. ("New Found" or the "Company") (TSXV: NFG) (NYSE American: NFGC) is pleased to announce that it has arranged a non-brokered...

Merck known as MSD outside the United States and Canada, is voluntarily recalling one lot of CUBICIN® 500 mg for intravenous use, Lot 934778, Exp June 2022. Because treatment with CUBICIN is likely to be initiated at a hospital or other monitored healthcare setting, the recall is being conducted to the user level, including hospital and administering institutions. Approximately 22,000 vials are affected by this ...